Cargando…

A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

BACKGROUND: Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patients initiating fremanezumab therapy. METHODS: Data were obtained for this retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krasenbaum, Lynda J., Pedarla, Vasantha L., Thompson, Stephen F., Tangirala, Krishna, Cohen, Joshua M., Driessen, Maurice T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066733/ https://www.ncbi.nlm.nih.gov/pubmed/35508970 http://dx.doi.org/10.1186/s10194-022-01413-z

Ejemplares similares

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
por: McAllister, Peter, et al.
Publicado: (2021)

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
por: Driessen, Maurice T., et al.
Publicado: (2022)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials”. Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819–828. Epublished November 2020
por: Barash, Steve, et al.
Publicado: (2021)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
por: Ohtani, Seiya, et al.
Publicado: (2023)

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
por: Nahas, Stephanie J., et al.
Publicado: (2021)

Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
por: Nahas, Stephanie J., et al.
Publicado: (2022)

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
por: Suzuki, Shiho, et al.
Publicado: (2023)

Fremanezumab for migraine
Publicado: (2020)

Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries
por: Cohen, Joshua, et al.
Publicado: (2020)

Effect of fremanezumab on quality of life and productivity in patients with chronic migraine
por: Lipton, Richard B., et al.
Publicado: (2020)

Fremanezumab: First Global Approval
por: Hoy, Sheridan M.
Publicado: (2018)

Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy
por: Tsioufis, Konstantinos, et al.
Publicado: (2021)

Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses
por: Fiedler‐Kelly, Jill, et al.
Publicado: (2020)

Correction to: Fremanezumab: First Global Approval
por: Hoy, Sheridan M.
Publicado: (2019)

Fremanezumab in the treatment of migraines: evidence to date
por: Robblee, Jennifer, et al.
Publicado: (2019)

Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine
por: Friedman, Deborah I., et al.
Publicado: (2020)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
por: Cullum, Christopher Kjaer, et al.
Publicado: (2023)

Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
por: Goadsby, Peter J., et al.
Publicado: (2020)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma
por: Kawamura, Shin, et al.
Publicado: (2022)

Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
por: Dupclay, Leon, et al.
Publicado: (2012)

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
por: Fiedler‐Kelly, Jill B., et al.
Publicado: (2019)

Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
por: Ferrari, Michel D., et al.
Publicado: (2022)

Fremanezumab for migraine prevention: more effective, less costly
Publicado: (2020)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review
por: Fatoye, F, et al.
Publicado: (2019)

Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
por: Straube, Andreas, et al.
Publicado: (2023)

Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
por: Vikelis, Michail, et al.
Publicado: (2023)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
por: Nowaczewska, Magdalena, et al.
Publicado: (2022)

Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review
por: Rhyne, Christopher, et al.
Publicado: (2023)

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
por: McAllister, Peter, et al.
Publicado: (2022)

Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs
por: Baser, Onur, et al.
Publicado: (2013)

Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
por: Argyriou, Andreas A., et al.
Publicado: (2023)

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
por: Lipton, Richard B., et al.
Publicado: (2021)

Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
por: Diener, Hans Christoph, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vkdspks6le1ffea2od39oc1jdu